Last week, the US Drug Enforcement Administration announced a move to reclassify marijuana as a Schedule III drug, after the Biden administration requested a review in late 2022. For decades, cannabis has been classified as Schedule I alongside drugs like heroin and LSD—and research on its effects and medical use has been limited. While rescheduling could lead to more clinical research on marijuana, the future is currently hazy. Today on The Weeds: what rescheduling cannabis means for medical research, and why it still might not be enough to push past the barriers that still exist.
Read More:
Marijuana could be classified as a lower-risk drug. Here’s what that means. - Vox
What marijuana reclassification means for the United States
Submit your policy questions!
We want to know what you’re curious about.
Credits:
Jonquilyn Hill, host
Sofi LaLonde, producer
Cristian Ayala, engineer
A.M. Hall, editorial director of talk podcasts
Want to support The Weeds? Please consider making a donation to Vox: bit.ly/givepodcasts
Please take a second to help us learn more about you! vox.com/podcastsurvey
Learn more about your ad choices. Visit podcastchoices.com/adchoices
A new era of cannabis research | Explain It to Me podcast - Listen or read transcript on Metacast
